CORTICOSTEROID THERAPY FOR ACUTE ASTHMA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/2x3q3x14Abstract
Background: Asthma is a chronic inflammatory disorder of the airways which affects 300 million people worldwide. Asthma places a huge burden in multiple nations. The main care components for asthma include assessment and monitoring, patient education, addressing environmental controls and comorbid conditions, and pharmaceutical therapy. Corticosteroids therapy is used for maintenance of asthma. While Systemic corticosteroids are often regarded as the firstline treatment for acute asthma since they are unmistakably linked to a quicker recovery to baseline function.
The aim: This study aims to show effectiveness of corticosteroid therapy for acute asthma.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and ScienceDirect, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Results: In the PubMed database, the results of our search brought up 60 articles, whereas the results of our search on ScienceDirect brought up 117 articles. The results of the search conducted by title screening yielded a total 15 articles for PubMed and 7 articles for ScienceDirect. We compiled a total of 9 papers, 6 of which came from PubMed and 3 of which came from ScienceDirect. We excluded 1 duplicate article and 1 review article. In the end, we included seven research (RCT) that met the criteria.
Conclusion: Corticosteroids therapy, whether oral, intravenous and inhaled, is effective to increase lung function (PEF), improve symptoms, and has fewer side effects. Corticosteroids therapy is also effective to reduce admission or hospitalization rate in severe acute asthma.
References
National Asthma Education. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl).
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Vol. 7, Frontiers in Pediatrics. Frontiers Media S.A.; 2019.
Enilari O, Sinha S. The global impact of asthma in adult populations. Vol. 85, Annals of Global Health. Ubiquity Press; 2019. p. 1–7.
Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Vol. 30, European Respiratory Review. European Respiratory Society; 2021.
Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Vol. 42, Seminars in Immunopathology. Springer; 2020. p. 5–15.
Nanda A, Wasan AN. Asthma in Adults. Vol. 104, Medical Clinics of North America. W.B. Saunders; 2020. p. 95– 108.
Lugogo N, Que LG, Carr TF, Kraft M. Asthma: Diagnosis and Management. In: Murray & Nadel’s Textbook of Respiratory Medicine. 2023. p. 831–49.
Trivedi M, Denton E. Asthma in children and adults—what are the differences and what can they tell us about asthma? Vol. 7, Frontiers in Pediatrics. Frontiers Media S.A.; 2019.
Alangari AA, Malhis N, Mubasher M, Al-Ghamedi N, Al-Tannir M, Riaz M, et al. Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children: A double-blind, randomized, controlled trial. Chest. 2014;145(4):772–8.
Cronin JJ, McCoy S, Kennedy U, An Fhailí SN, Wakai A, Hayden J, et al. A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department. Ann Emerg Med. 2016 May 1;67(5):593-601.e3.
Demirca BP, Cagan H, Kiykim A, Arig U, Arpa M, Tulunay A, et al. Nebulized fluticasone propionate, a viable alternative to systemic route in the management of childhood moderate asthma attack: A double-blind, doubledummy study. Respir Med. 2015 Sep 1;109(9):1120–5.
Gummalla P, Weaver D, Ahmed Y, Shah V, Keenaghan M, Doymaz S. Intravenous methylprednisolone versus intravenous methylprednisolone combined with inhaled budesonide in acute severe pediatric asthma. Journal of Asthma. 2021;58(11):1512–7.
Marghli S, Bouhamed C, Sghaier A, Chebbi N, Dlala I, Bettout S, et al. Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial. BMC Emerg Med. 2022 Dec 1;22(1).
Martins DT, Carlos K, Carvalho LB, Prado LB, Fransolin C, Atallah AN, et al. A randomized clinical trial on inhaled ciclesonide for managing acute asthma in the emergency room. Sao Paulo Medical Journal. 2022;140(3):430–8.
Rehrer MW, Liu B, Rodriguez M, Lam J, Alter HJ. A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma. Ann Emerg Med. 2016 Nov 1;68(5):608–13.
Shefrin AE, Goldman RD. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients [Internet] Vol. 55, Canadian Family Physician • Le Médecin de famille canadien. 2009. Available from: www.nhlbi.nih.gov/guidelines/asthma/
Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Vol. 201, American Journal of Respiratory and Critical Care Medicine. American Thoracic Society; 2020. p. 276–93.
Global Initiative For Asthma (GINA). Pocket Guide For Asthma Management And Prevention. 2023;
Mendes ES, Cadet L, Arana J, Wanner A. Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma. Chest. 2015 Apr 1;147(4):1037–42.
Dzaren JM, Bel EH. Asthma. In: Goldman-Cecil Medicine. 27th ed. Elsevier; 2023. p. 537–47
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
